Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

TALTZ® (ixekizumab): Relapse in Plaque Psoriasis Following Discontinuation

For ixekizumab responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse was 164 days.

Detailed Information

  • For the analyses summarized below, response was defined as a sPGA score of 0 (clear skin) or 1 (minimal) and relapse was defined as a sPGA score of >3.1

  • In 2 phase 3 clinical trials, patients who were originally randomized to ixekizumab and who responded to treatment at week 12 were re-randomized to an additional 48 weeks of ixekizumab 80 mg Q4W or placebo.1

  • In those week 12 responders to ixekizumab who were re-randomized to treatment withdrawal (ie, placebo), 7% maintained their clinical response at week 60. The median time to relapse was 164 days.1

  • In responders who were re-randomized to treatment with ixekizumab Q4W, 75% maintained their response at week 60.1

  • Detailed clinical trial design information is available upon request.

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

Reference

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.

Glossary

Q4W = every 4 weeks

sPGA = static Physician Global Assessment

Additional related information

Date of Last Review: September 17, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical